WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Short Interest Down 32.6% in August

Posted by on Sep 2nd, 2026

WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY – Get Free Report) was the target of a large drop in short interest during the month of August. As of August 14th, there was short interest totaling 31,255 shares, a drop of 32.6% from the July 30th total of 46,353 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 61,760 shares, the short-interest ratio is currently 0.5 days.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of WuXi Biologics (Cayman) to a “hold” rating in a report on Friday, August 28th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of “Hold”.

Get Our Latest Research Report on WuXi Biologics (Cayman)

WuXi Biologics (Cayman) Price Performance

Shares of OTCMKTS:WXXWY opened at $12.80 on Wednesday. The business’s 50 day moving average is $10.53 and its 200 day moving average is $9.42. WuXi Biologics has a 52-week low of $7.30 and a 52-week high of $13.43.

WuXi Biologics (Cayman) Company Profile

(Get Free Report)

WuXi Biologics (Cayman) Inc, trading OTC as WXXWY, is a global contract research, development and manufacturing organization (CDMO) specializing in biologics. Founded as a spin-out from WuXi AppTec and incorporated in the Cayman Islands in 2017, the company offers end-to-end support across the biologics value chain. Its service portfolio encompasses discovery biology, analytical development, process chemistry and large-scale manufacturing for therapeutic proteins and antibodies.

The firm’s core offerings include the development of monoclonal antibodies, recombinant proteins and cell and gene therapy vectors.

Featured Stories

Receive News & Ratings for WuXi Biologics (Cayman) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi Biologics (Cayman) and related companies with MarketBeat.com's FREE daily email newsletter.